dc.contributor.author | Sarathy, Kiran | |
dc.contributor.author | Wells, George A. | |
dc.contributor.author | Singh, Kuljit | |
dc.contributor.author | Couture, Etienne | |
dc.contributor.author | Chong, Aun-Yeong | |
dc.contributor.author | Rubens, Fraser | |
dc.contributor.author | Lordkipanidzé, Marie | |
dc.contributor.author | Tanguay, Jean-Francois | |
dc.contributor.author | So, Derek Y. F. | |
dc.date.accessioned | 2021-02-23T14:23:36Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2021-02-23T14:23:36Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://hdl.handle.net/1866/24874 | |
dc.publisher | Wiley | fr |
dc.rights | Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License. | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Acute coronary syndrome | fr |
dc.subject | Antiplatelet | fr |
dc.subject | Coronary artery bypass graft surgery | fr |
dc.title | Platelet quiescence in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de pharmacie | fr |
dc.identifier.doi | 10.1161/JAHA.120.016602 | |
dcterms.abstract | BACKGROUND: The optimal antiplatelet strategy for patients with acute coronary syndromes who require coronary artery
bypass surgery remains unclear. While a more potent antiplatelet regimen will predispose to perioperative bleeding, it is
hypothesized that through “platelet quiescence,” ischemic protection conferred by such therapy may provide a net clinical
benefit.
METHODS AND RESULTS: We compared patients undergoing coronary artery bypass surgery who were treated with a more potent antiplatelet inhibition strategy with those with a less potent inhibition through a meta-analysis. The primary outcome was
all-cause mortality after bypass surgery. The analysis identified 4 studies in which the antiplatelet regimen was randomized
and 6 studies that were nonrandomized. Combining all studies, there was an overall higher mortality with weaker strategies
compared with more potent strategies (odds ratio, 1.38; 95% CI, 1.03–1.85; P=0.03).
CONCLUSIONS: Our findings support the concept of platelet quiescence, in reducing mortality for patients with acute coronary
syndrome requiring coronary artery bypass surgery. This suggests the routine up-front use of potent antiplatelet regimens in
acute coronary syndrome, irrespective of likelihood of coronary artery bypass graft. | fr |
dcterms.isPartOf | urn:ISSN:2047-9980 | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | https://pubmed.ncbi.nlm.nih.gov/33599134/ | fr |
UdeM.VersionRioxx | Version publiée / Version of Record | fr |
oaire.citationTitle | Journal of the American Heart Association | fr |
oaire.citationVolume | 10 | fr |